Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men

References

• Morales A, Lunenfeld B. International society for the study of the aging male. Aging male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male. 2002;5(2):74–86.
   PubMedGoogle Scholar
• Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2005;8(2):56–58.
   PubMedGoogle Scholar
• Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12(1):5–12.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Kalinchenko S, et al. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male. 2013;16(4):143–150.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369–386.
   PubMed Web of Science ®Google Scholar
• Al-Sharefi A, Quinton R. Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab. 2020;35(3):526–540.
   Google Scholar
• Trinick TR, Feneley MR, Welford H, et al. International web survey shows high prevalence of symptomatic testosterone deficiency in men. Aging Male. 2011;14(1):10–15.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in Middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Tarocchi M, et al. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest. 2016;39(4):473–484.
   PubMed Web of Science ®Google Scholar
• Petak SM, Nankin HR ,Spark RF, et al. American association of clinical endocrinologists. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients–2002 update. Endocr Pract. 2002; 8(6):440–456.
   PubMedGoogle Scholar
• Lejeune H, Huyghe É, Droupy S. Diminution du désir sexuel et déficit en testostérone chez l'homme [hypoactive sexual desire and testosterone deficiency in men]. Prog Urol. 2013;23(9):621–628.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. Aging Male. 2012;15(4):187–197.
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Ricca V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl. 2009;32(6):720–728.
   PubMedGoogle Scholar
• Salonia A, Rastrelli G, Hackett G, et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019;5(1):38.
   PubMedGoogle Scholar
• Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067–1075.
   PubMed Web of Science ®Google Scholar
• Millar AC, Lau ANC, Tomlinson G, et al. Predicting low testosterone in aging men: a systematic review. CMAJ. 2016;188(13):E321–E330.
   PubMed Web of Science ®Google Scholar
• Morley JE, Perry HM, Kevorkian RT, et al. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53(4):424–429.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu ZY, Wang LH, et al. Are the aging male’s symptoms (AMS) scale and the androgen deficiency in the aging male (ADAM) questionnaire suitable for the screening of late-onset hypogonadism in aging Chinese men? Aging Male. 2013;16(3):92–96.
   PubMed Web of Science ®Google Scholar
• Rabah DM, Altaweel W, Arafa MA. Clinical assessment and validation of an Arabic aging male symptoms questionnaire in patients with androgen deficiency. Aging Male. 2011;14(1):33–36.
   PubMed Web of Science ®Google Scholar
• Behre HM, Tammela TL, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012;15(4):198–207.
   PubMed Web of Science ®Google Scholar
• Zengerling F, Schrader AJ, Cronauer MV, et al. The “aging males’ symptoms” scale (AMS): predictive value for lowered circulating androgens. Aging Male. 2012;15(4):253–257.
   PubMed Web of Science ®Google Scholar
• Lee CP, Jiang JR, Chen Y, et al. The “aging males’ symptoms” (AMS) scale assesses depression and anxiety. Aging Male. 2013;16(3):97–101.
   PubMed Web of Science ®Google Scholar
• Moore C, Huebler D, Zimmermann T, et al. The aging males’ symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46(1):80–87.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and international index of erectile function-5 questionnaires. Aging Male. 2012;15(2):111–114.
   PubMed Web of Science ®Google Scholar
• Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulinresistance: pathophysiology and management. Am J Clin Dermatol. 2004;5(3):199–203.
   PubMed Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131–143.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(2):337–353.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Pye SR, et al. European male aging study group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab. 2008;93(7):2737–2745.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–4247.
   PubMed Web of Science ®Google Scholar
• Schneider G, Nienhaus K, Gromoll J, et al. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry. 2011;19(3):274–283.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Maggi M. Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl. 2020;22(3):265–273.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–4343.
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2008;60(7):762–769.
   Web of Science ®Google Scholar
• Kaplan SA, O’Neill E, Lowe R, et al. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the proscar long-term efficacy and safety study (PLESS). Aging Male. 2013;16(2):48–51., Jun Epub 2013 Mar 12. PMID: 23480623.
   PubMed Web of Science ®Google Scholar
• Schatzl G, Brössner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The prostate study group of the Austrian society of urology. Urology. 2000;55(3):397–402.
   PubMed Web of Science ®Google Scholar
• Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am. 2006;20(4):909–923.
   PubMed Web of Science ®Google Scholar
• Choong K, Basaria S. Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male. 2010;13(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–244.
   PubMed Web of Science ®Google Scholar
• Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176(6):2443–2447.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109(4):802–810.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SW. Testosterone and chronic prostatitis/chronic pelvic pain syndrome: a propensity score-matched analysis. J Sex Med. 2016;13(7):1047–1055.
   PubMed Web of Science ®Google Scholar
• Kato Y, Shigehara K, Kawaguchi S, et al. Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: a subanalysis of a prospective randomised controlled study in Japan (EARTH study). Andrologia. 2020;52(9):e13768.
   PubMed Web of Science ®Google Scholar
• White HD, Brown LA, Gyurik RJ, et al. Treatment of pain in fibromyalgia patients with testosterone gel: pharmacokinetics and clinical response. Int Immunopharmacol. 2015;27(2):249–256.
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren LJ. Late onset hypogonadism of men is not equivalent to the menopause. Maturitas. 2014;79(1):52–57.
   PubMed Web of Science ®Google Scholar
• Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104–120.
   PubMed Web of Science ®Google Scholar
• Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European male ageing study. Eur J Endocrinol. 2012;166(1):77–85.
   PubMed Web of Science ®Google Scholar
• Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011;43(03):223–225.
   PubMedGoogle Scholar
• Wehr E, Pilz S, Boehm BO, et al. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol. 2010;73(2):243–248. Epub 2009 Dec 29. PMID: 20050857.
   PubMed Web of Science ®Google Scholar
• Rafiq R, van Schoor NM, Sohl E, et al. Associations of vitamin D status and vitamin D-related polymorphisms with sex hormones in older men. J Steroid Biochem Mol Biol. 2016;164:11–17.
   PubMed Web of Science ®Google Scholar
• D’Andrea S, Martorella A, Coccia F, et al. Relationship of vitamin D status with testosterone levels: a systematic review and Meta-analysis. Endocrine. 2021;72(1):49–61.
   PubMed Web of Science ®Google Scholar
• Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–1562.
   PubMed Web of Science ®Google Scholar
• Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499.
   PubMed Web of Science ®Google Scholar
• Brochmann H, Bjøro T, Gaarder PI, et al. Prevalence of thyroid dysfunction in elderly subjects. A randomized study in a Norwegian rural community (Naerøy). Acta Endocrinol. 1988;117(1):7–12.
   PubMedGoogle Scholar
• Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid. 2011;21(1):5–11.
   PubMed Web of Science ®Google Scholar
• Fischer S, Ehlert U, Amiel Castro R. Hormones of the hypothalamic-pituitary-gonadal (HPG) axis in male depressive disorders - A systematic review and Meta-analysis. Front Neuroendocrinol. 2019;55:100792.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Few WL, 3rd, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab. 1996;81(11):4108–4112.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Kohn TP, Santiago JE, et al. Increased risk of hypogonadal symptoms in shift workers with shift work sleep disorder. Urology. 2020;138:52–59.
   PubMed Web of Science ®Google Scholar
• Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28 Suppl 2(Suppl 2):109–123.
   PubMedGoogle Scholar
• Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209–218.
   PubMed Web of Science ®Google Scholar
• Martens HF, Sheets PK, Tenover JS, et al. Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. J Rheumatol. 1994;21(8):1427–1431. PMID: 7983641.
   PubMed Web of Science ®Google Scholar
• Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57.
   PubMed Web of Science ®Google Scholar
• Aloisi AM, Aurilio C, Bachiocco V, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology. 2009;34 Suppl 1:S162–S8.
   PubMedGoogle Scholar
• Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. BMJ. 2010;341:c4462.
   PubMed Web of Science ®Google Scholar
• Basaria S, Travison TG, Alford D, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156(2):280–288.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Billeci D, Maggi M, et al. Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Invest. 2018;41(12):1377–1388.
   PubMed Web of Science ®Google Scholar
• Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab. 2010;95(10):4542–4548.
   PubMed Web of Science ®Google Scholar
• Antonio L, Wu FC, O’Neill TW, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101(7):2647–2657.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, O’Neill TW, Ahern T, et al. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: prospective results from the EMAS. Clin Endocrinol. 2018;89(4):459–469.
   PubMed Web of Science ®Google Scholar
• Kacker R, Hornstein A, Morgentaler A. Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male. 2013;16(4):164–168.
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Commentary: guideline for male testosterone therapy: a clinician’s perspective. J Clin Endocrinol Metab. 2007;92(2):416–417.
   PubMed Web of Science ®Google Scholar
• Giagulli VA, Castellana M, Lisco G, et al. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020;8(6):1628–1641.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672.
   PubMed Web of Science ®Google Scholar
• Keevil BG, Adaway J. Assessment of free testosterone concentration. J Steroid Biochem Mol Biol. 2019;190:207–211.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–2439.
   PubMed Web of Science ®Google Scholar
• Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a Meta-analysis study. J Sex Med. 2014;11(6):1577–1592.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000–1011.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967–981.
   PubMed Web of Science ®Google Scholar
• Krakowsky Y, Conners W, Morgentaler A. Serum concentrations of sex hormone-binding globulin vary widely in younger and older men: clinical data from a men’s health practice. Eur Urol Focus. 2019;5(2):273–279.
   PubMedGoogle Scholar
• Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3 Suppl):14–22.
   PubMedGoogle Scholar
• Morgentaler A, Khera M, Maggi M, et al. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014;11(7):1636–1645.
   PubMed Web of Science ®Google Scholar
• Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol. 2003;58(6):710–717.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Barqawi AB, O’Donnell C, et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int. 2007;100(3):509–513.
   PubMed Web of Science ®Google Scholar
• Guay A, Miller MG, McWhirter CL. Does early morning versus late morning draw time influence apparent testosterone concentration in men aged ≥45 years? Data from the hypogonadism in males study. Int J Impot Res. 2008;20(2):162–167.
   PubMed Web of Science ®Google Scholar
• Caronia LM, Dwyer AA, Hayden D, et al. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol. 2013;78(2):291–296.
   PubMed Web of Science ®Google Scholar
• Gagliano-Jucá T, Li Z, Pencina KM, et al. Oral glucose load and mixed meal feeding lowers testosterone levels in healthy eugonadal men. Endocrine. 2019;63(1):149–156.
   PubMed Web of Science ®Google Scholar
• Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22(15):3181–3186.
   PubMed Web of Science ®Google Scholar
• Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl. 2007;9(2):147–179.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res. 2009;37:52–61.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Pharmacogenetics of testosterone replacement therapy. Pharmacogenomics. 2009;10(8):1341–1349.
   PubMed Web of Science ®Google Scholar
• Holm AC, Fredrikson MG, Theodorsson E, et al. Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism. Aging Male. 2011;14(4):249–256.
   PubMed Web of Science ®Google Scholar
• Canale D, Caglieresi C, Moschini C, et al. Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin Endocrinol. 2005;63(3):356–361.
   PubMed Web of Science ®Google Scholar
• Berglund LH, Prytz HS, Perski A, et al. Testosterone levels and psychological health status in men from a general population: the Tromsø study. Aging Male. 2011;14(1):37–41.
   PubMed Web of Science ®Google Scholar
• Scovell JM, Ramasamy R, Wilken N, et al. Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dL. BJU Int. 2015;116(1):142–146.
   PubMed Web of Science ®Google Scholar
• Tajar A, McBeth J, Lee DM, et al. Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in Middle-aged and older European men. Pain. 2011;152(7):1495–1501.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Dicuio M, et al. Subclinical male hypogonadism. Minerva Endocrinol. 2020. doi:https://doi.org/10.23736/S0391-1977.20.03208-3
   Google Scholar
• Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol. 1996;155(2):529–533.
   PubMed Web of Science ®Google Scholar
• Bunch TJ, Abraham D, Wang S, et al. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. DAGM. 2002;5(1):38–46.
   Google Scholar
• Dalvi M, Walker BR, Strachan MW, et al. The prevalence of structural pituitary abnormalities by MRI scanning in men presenting with isolated hypogonadotrophic hypogonadism. Clin Endocrinol. 2016;84(6):858–861.
   PubMed Web of Science ®Google Scholar
• Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in Middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab. 2004;89(12):5920–5926.
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28(3 Suppl):28–31.
   PubMedGoogle Scholar
• Al-Sharefi A, Mohammed A, Abdalaziz A, et al. Androgens and anemia: current trends and future prospects. Front Endocrinol (Lausanne)). 2019;10:754.
   PubMed Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract. 2014;68(2):203–215.
   PubMed Web of Science ®Google Scholar
• Saad F, Caliber M, Doros G, et al. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23(1):81–92.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Mulay A, et al. Long-term testosterone therapy in type 2 diabetes is associated with decreasing waist circumference and improving erectile Function. World J Mens Health. 2020;38(1):68–77.
   PubMedGoogle Scholar
• Snyder PJ, Peachey H, Berlin JA, et al. Of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–2677.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male. 2012;15(2):96–102.
   PubMed Web of Science ®Google Scholar
• Haider A, Meergans U, Traish A, et al. Progressive improvement of T-Scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol. 2014;2014:1–9.
   Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in Middle-aged men: a Meta-analysis. Clin Endocrinol. 2005;63(3):280–293.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146–159.
   PubMedGoogle Scholar
• Rodriguez-Tolrà J, Torremadé Barreda J, del Rio L, et al. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. Aging Male. 2013;16(4):184–190.
   PubMed Web of Science ®Google Scholar
• Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes. 2013;3(3-4):73–83.
   PubMedGoogle Scholar
• Francomano D, Ilacqua A, Bruzziches R, et al. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. 2014;83(1):167–173.
   PubMed Web of Science ®Google Scholar
• Saad F, Doros G, Haider KS, et al. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study. Int J Obes. 2020;44(6):1264–1278.
   Web of Science ®Google Scholar
• Haider A, Yassin A, Doros G, et al. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:1–15.
   Web of Science ®Google Scholar
• Corona G, Torres LO, Maggi M. Testosterone therapy: what We have learned from trials. J Sex Med. 2020;17(3):447–460.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology. 2020;8(6):1519–1529.
   PubMed Web of Science ®Google Scholar
• Krasnoff JB, Basaria S, Pencina MJ, et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham offspring study. J Clin Endocrinol Metab. 2010;95(6):2790–2799.
   PubMed Web of Science ®Google Scholar
• Walsh JS, Marshall H, Smith IL, et al. Testosterone replacement in young male cancer survivors: a 6-month double-blind randomised placebo-controlled trial. PLOS Med. 2019;16(11):e1002960.
   PubMed Web of Science ®Google Scholar
• Kacker R, Conners W, Zade J, et al. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol. 2014;191(4):1072–1076.
   PubMed Web of Science ®Google Scholar
• Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1861–1870.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone. 2009;44(5):734–743.
   PubMed Web of Science ®Google Scholar
• Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802–1822.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–479.
   PubMed Web of Science ®Google Scholar
• Aminorroaya A, Kelleher S, Conway AJ, et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol. 2005;152(6):881–886.
   PubMed Web of Science ®Google Scholar
• Pizzocaro A, Vena W, Condorelli R, Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis. J Endocrinol Invest. 2020;43(12):1675–1687.
   PubMed Web of Science ®Google Scholar
• Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166(19):2124–2131.
   PubMedGoogle Scholar
• Rosenberg EA, Bůžková P, Fink HA, et al. Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: the cardiovascular health study. Metabolism. 2021;114:154399.
   PubMed Web of Science ®Google Scholar
• Nethander M, Vandenput L, Eriksson AL, et al. Evidence of a causal effect of estradiol on fracture risk in Men. J Clin Endocrinol Metab. 2019;104(2):433–442.
   PubMed Web of Science ®Google Scholar
• Algeffari M, Jayasena CN, MacKeith P, et al. Testosterone therapy for sexual dysfunction in men with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2018;35(2):195–202.
   PubMed Web of Science ®Google Scholar
• Haider KS, Haider A, Doros G, et al. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199(1):257–265.
   PubMed Web of Science ®Google Scholar
• Cunningham GR, Stephens-Shields AJ, Rosen RC, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101(8):3096–3104.
   PubMed Web of Science ®Google Scholar
• Brock G, Heiselman D, Maggi M, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195(3):699–705.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Saghir A, et al. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int. 2016;118(5):804–813.
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Kozlov GI, Gontcharov NP, et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003;6(2):94–99.
   PubMedGoogle Scholar
• Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10(2):579–588.
   PubMed Web of Science ®Google Scholar
• Tan WS, Ng CJ, Khoo EM, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic asian men study (the subang men's health study). Aging Male. 2011;14(4):231–236. Dec PMID: 22115177.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911–917.
   PubMed Web of Science ®Google Scholar
• Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the european male aging study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508–1516.
   PubMed Web of Science ®Google Scholar
• Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology. 2013;82(4):814–819.
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272–283.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in Middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–3503.
   PubMed Web of Science ®Google Scholar
• Strollo F, Strollo G, Morè M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male. 2013;16(2):33–37.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733.
   PubMedGoogle Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21(3):158–169.
   PubMed Web of Science ®Google Scholar
• Li SY, Zhao YL, Yang YF, et al. Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: a Meta-Analysis. Int J Endocrinol. 2020;2020:1–12.
   Web of Science ®Google Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45.
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–2079.
   PubMed Web of Science ®Google Scholar
• Groti Antonič K, Antonič B, Žuran I, et al. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male. 2020;23(5):1442–1413.
   PubMed Web of Science ®Google Scholar
• Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30(11):1029–1034.
   PubMed Web of Science ®Google Scholar
• Kang SM, Jang Y, Kim Ji Chung N, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol. 2002;89(7):862–864.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as indicator of vascular damage in middle-aged overweight men. J Androl. 2008;29:54–55.
   Google Scholar
• Nettleship JE, Pugh PJ, Channer KS, et al. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res. 2007;39(5):366–371.
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled moscow study. Clin Endocrinol. 2010;73(5):602–612.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):R25–45.
   PubMed Web of Science ®Google Scholar
• Vodo S, Bechi N, Petroni A, et al. Testosterone-induced effects on lipids and inflammation. Mediators Inflamm. 2013;2013:183041
   PubMed Web of Science ®Google Scholar
• Wallis CJ, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4(6):498–506.
   PubMed Web of Science ®Google Scholar
• Tan RS, Cook KR, Reilly WG. Myocardial infarction and stroke risk in young healthy men treated with injectable testosterone. Int J Endocrinol. 2015;2015:1–8
   Web of Science ®Google Scholar
• Loo SY, Azoulay L, Nie R, et al. Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort Study. Am J Med. 2019;132(9):1069–1077.e4.
   PubMed Web of Science ®Google Scholar
• Sesti F, Pofi R, Minnetti M, et al. Late-onset hypogonadism: reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology. 2020;8(6):1614–1627.
   PubMed Web of Science ®Google Scholar
• Traish AM, Hackett G, Miner M, et al. Cardiovascular and cerebrovascular safety of testosterone therapy. Am J Med. 2019;132(10):e748.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Dicuio M, Reismann Y, et al. Cardiovascular impact of testosterone therapy for hypogonadism. Expert Rev Cardiovasc Ther. 2018;16(9):617–625.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260–1271.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Testosterone and cardiovascular risk: meta-analysis of interventional Studies. J Sex Med. 2018;15(6):820–838.
   PubMed Web of Science ®Google Scholar
• Park S, Gale SE, Watson K. The role of testosterone in patients with heart failure: a systematic review. Cardiol Rev. 2021;29(3):156–161.
   PubMed Web of Science ®Google Scholar
• Oni OA, Dehkordi SHH, Jazayeri MA, et al. Relation of testosterone normalization to mortality and myocardial infarction in men with previous myocardial infarction. Am J Cardiol. 2019;124(8):1171–1178.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Morgentaler A, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc. 2015;90(8):1038–1045.
   PubMed Web of Science ®Google Scholar
• Houghton DE, Alsawas M, Barrioneuvo P, et al. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2018;172:94–103.
   PubMed Web of Science ®Google Scholar
• Martinez C, Suissa S, Rietbrock S, et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016;355:i5968.
   PubMedGoogle Scholar
• Corona G, Dicuio M, Rastrelli G, et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Investig Med. 2017;65(6):964–973.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–3019.
   PubMed Web of Science ®Google Scholar
• Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the health in menstudy. J Clin Endocrinol Metab. 2012;97(1):179–189.
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050–2058.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–733.
   PubMed Web of Science ®Google Scholar
• Yeap BB. Testosterone therapy and mortality in US veterans. Asian J Androl. 2012;14(5):667–668.
   PubMed Web of Science ®Google Scholar
• Wu FC. Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab. 2012;97(6):1884–1886.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Marriott RJ, Antonio L, et al. Serum testosterone is inversely, and sex hormone-binding globulin directly, associated with all-cause mortality in men. J Clin Endocrinol Metab. 2021;106(2):e625–e637.
   PubMed Web of Science ®Google Scholar
• Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289–305.
   PubMed Web of Science ®Google Scholar
• Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31–40.
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572–2582.
   PubMed Web of Science ®Google Scholar
• Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the testim registry in the US (TRiUS). Aging Male. 2012;15(1):14–21.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598–1605.
   PubMed Web of Science ®Google Scholar
• Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A. 1997;94(14):7537–7542.
   PubMed Web of Science ®Google Scholar
• Maggio M, Dall’Aglio E, Lauretani F, et al. The hormonal pathway to cognitive impairment in older men. J Nutr Health Aging. 2012;16(1):40–54.
   PubMed Web of Science ®Google Scholar
• Tan S, Sohrabi HR, Weinborn M, et al. Effects of testosterone supplementation on separate cognitive domains in cognitively healthy older men: a meta-analysis of current randomized clinical trials. Am J Geriatr Psychiatry. 2019;27(11):1232–1246
   PubMed Web of Science ®Google Scholar
• Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006;10(2):77–82.
   PubMed Web of Science ®Google Scholar
• Etgen T, Sander D, Bickel H, et al. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int. 2011;108(44):743–750.
   PubMed Web of Science ®Google Scholar
• Lv W, Du N, Liu Y, et al. Low testosterone level and risk of alzheimer’s disease in the elderly men: a systematic review and meta-Analysis. Mol Neurobiol. 2016;53(4):2679–2684.
   PubMed Web of Science ®Google Scholar
• Corona G, Guaraldi F, Rastrelli G, et al. Testosterone deficiency and risk of cognitive disorders in aging males. World J Mens Health. 2021;39(1):9–18.
   PubMedGoogle Scholar
• Kim JW, Oh MM, Yoon CY, et al. Nocturnal polyuria and decreased serum testosterone: is there an association in men with lower urinary tract symptoms? Int J Urol. 2014;21(5):518–523.
   PubMed Web of Science ®Google Scholar
• Pearl JA, Berhanu D, François N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828–1833.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011;14(1):53–58.
   PubMed Web of Science ®Google Scholar
• Yassin DJ, El Douaihy Y, Yassin AA, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol. 2014;32(4):1049–1054.
   PubMed Web of Science ®Google Scholar
• Kalinchenko S, Vishnevskiy EL, Koval AN, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008;11(2):57–61.
   PubMed Web of Science ®Google Scholar
• Teeling F, Raison N, Shabbir M, et al. Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis. Urology. 2019;126:16–23.
   PubMed Web of Science ®Google Scholar
• Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis. Urol Oncol. 2019;37(10):637–646.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lipshultz LI, Bennett R, et al. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–1260.
   PubMedGoogle Scholar
• Giganti F, Moore CM. Magnetic resonance imaging in active surveillance-a modern approach. Transl Androl Urol. 2018;7(1):116–131.
   PubMed Web of Science ®Google Scholar
• Ory J, Flannigan R, Lundeen C, et al. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016;196(4):1082–1089.
   PubMed Web of Science ®Google Scholar
• Kacker R, Hult M, San Francisco IF, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18(1):16–20.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–320.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Benesh JA, Denes BS, et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med. 2014;11(11):2818–2825.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Vignozzi L, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013;10(10):2518–2528.
   PubMed Web of Science ®Google Scholar
• Lopez DS, Advani S, Tsilidis KK, et al. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk? Transl Androl Urol. 2017;6(3):566–579.
   PubMed Web of Science ®Google Scholar
• Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170–183.
   PubMedGoogle Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–2575.
   PubMed Web of Science ®Google Scholar
• Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118(5):731–741.
   PubMed Web of Science ®Google Scholar
• Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015;193(1):80–86.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in Middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–1457.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zong H, Yan H, et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132–143.
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482–492.
   PubMed Web of Science ®Google Scholar
• Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215–2220.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Maggi M, Corona G. Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol. 2018;11(4):439–458.
   PubMed Web of Science ®Google Scholar
• Chen YW, Niu YH, Xu H, et al. Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study. Asian J Androl. 2019;21(4):413–418.
   PubMed Web of Science ®Google Scholar
• Hsieh TC, Pastuszak AW, Hwang K, et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647–650.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Mannucci E, et al. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology. 2014;2(6):794–808.
   PubMed Web of Science ®Google Scholar
• Rambhatla A, Mills JN, Rajfer J. The role of estrogen modulators in male hypogonadism and infertility. Rev Urol. 2016;18(2):66–72.
   PubMedGoogle Scholar
• Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–1022.
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Lee H, Leder BZ, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016;126(3):1114–1125.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–3478.
   PubMed Web of Science ®Google Scholar
• Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–327.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Junker R, Kamischke A, et al. Contraceptive steroids influence the hemostatic activation state in healthy men. J Androl. 2002;23(4):503–511.
   PubMedGoogle Scholar